Recently, the FDA announced the granting of a New Drug Priority Approval Application (NDA) for tucatinib in combination with trastuzumab and capecitabine for the treatment of locally advanced unresectable or metastatic HER-2-positive breast cancer, including patients with brain metastases. Here, ERBB2 is linked to breast carcinoma.